[Sensitivity and specificity of meta-iodobenzylguanidine (mIBG) scintigraphy in the evaluation of XXXX : analysis of 115 cases].

@entity1 @entity5 @entity3 @entity521 @entity236 @entity2661
Seventy @entity1 (3.7 +/- 3.3 y) with definitely confirmed diagnosis of @entity521 had 115 whole body scans carried out 24 h after injection of 3.7 MBq/kg of I-123 mIBG (83 scans) or 0.7 MBq/kg of I-131 mIBG (17 scans) or 0.9 to 4.5 GBq of I-131 mIBG (15 post-therapeutic scans). The scans were interpreted as positive in the presence of any non-physiological uptake area or of any bone uptake of the tracer, even at the level of the metaphyseal complex. For the primary @entity5 , the sensitivity of mIBG scans was 73%. Ten false negative @entity1 had an overlap of the @entity5 with the bladder or heart images (4 cases) or with positive metastatic images (6 cases: liver, spine). Three false negative @entity1 had @entity521 which did not secrete @entity2661 . The specificity of mIBG was 94%. In our opinion, mIBG scans have a complementary role to assess the activity of post-therapeutic remnants. For the detection of hepatic and lymph node @entity3 , the sensitivity was about 50% and the specificity was 100%. The standard used for the detection of bone marrow @entity3 was the cytological and histological examination of 10 @entity236 and one or more biopsies (CHBMS). The sensitivity of mIBG scans was 90% and the specificity 68%. However, reviewing the data from the 16 false positive scans, we found 11 definitely proven bone @entity3 , 3 biological relapses and 2 cases of delayed abnormal CHBMS supporting the positivity of the mIBG scans, raising the specificity to 100%. Tc-99m diphosphonate bone scans had a sensitivity of 78% and a specificity of 51%. We suggest that positive mIBG scans may save other procedures since our data do not support false positive detection of bone or bone marrow @entity3 . In contrast, @entity1 with negative mIBG findings should be further explored.
